Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
With
ImmunoGen, Inc.
MorphoSys AG
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Availability of tumor tissue for mesothelin expression testing and for further biomarker analysis
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (or for thymic carcinoma, at least one measurable lesion per International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 criteria
Adequate bone marrow, liver, renal and coagulation function
Left ventricular ejection fraction (LVEF) ≥ 50% of the lower limit of normal (LLN) according to local institutional ranges
Eastern Cooperative Oncology Group (ECOG) 0 or 1
You may not be if
Exposure to more than one prior anti-tubulin/microtubule agent
Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition
Symptomatic Central nervous system (CNS) metastases and/or carcinomatous meningitis
Contraindication to both CT and MRI contrast agents
Active hepatitis B or C infection
Pregnant or breast-feeding patients
Clareo Health | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
